In short
GSKVX000000077430 is an investigational vaccine being studied for the prevention of influenza. It is being tested in two Phase 3 trials involving a total of 57,000 adults. One trial focuses on adults aged 65 and older, while the other studies adults aged 18 to 64.
Key points
- GSKVX000000077430 is an investigational influenza vaccine.
- It is being studied in two Phase 3 clinical trials.
- The trials include a total of 57,000 participants.
- One trial focuses on adults aged 65 and older.
- The other trial studies adults aged 18 to 64.
- The vaccine is given as a 0.5 ml intramuscular injection.
What is GSKVX000000077430?
GSKVX000000077430 is an investigational influenza vaccine. It is being developed to protect against influenza, also known as the flu. The vaccine is being studied in adults aged 18 years and older.
How does GSKVX000000077430 work?
The clinical trial records describe GSKVX000000077430 as a vaccine against influenza. The vaccine is designed to stimulate an immune response against influenza virus subtypes, including influenza A subtypes H1N1 and H3N2, as well as influenza B/Victoria lineage. The exact mechanism of action is not described in the available data.
Which conditions is GSKVX000000077430 studied for?
- Influenza, Human — a respiratory infection caused by influenza viruses. The vaccine aims to prevent laboratory-confirmed influenza illness caused by specific virus subtypes.
How is GSKVX000000077430 given?
GSKVX000000077430 is given as an intramuscular injection. The dose volume is 0.5 millilitres.
What do the clinical trials show?
GSKVX000000077430 is being investigated in two Phase 3 clinical trials. These are large, late-stage studies designed to evaluate both efficacy and safety.
The first trial (2026-526682-14-00) is studying the vaccine in 54,000 adults aged 65 years and older. This trial compares GSKVX000000077430 against Efluelda, an approved high-dose trivalent influenza vaccine. The main goal is to demonstrate that GSKVX000000077430 is not inferior to Efluelda in preventing laboratory-confirmed influenza illness caused by influenza A subtypes H1N1 or H3N2 or influenza B/Victoria.
The second trial (2026-526925-17-00) is studying the vaccine in 3,000 adults aged 18 to 64 years. This trial compares the immune response to GSKVX000000077430 in younger adults against the immune response in adults aged 65 and older from the first trial. It also compares GSKVX000000077430 against Alpharix, a trivalent influenza vaccine.
Both trials are currently authorised, meaning they have received regulatory approval to proceed.
Who can take part in these trials?
The two trials enrol different age groups. The first trial includes adults aged 65 years and older. The second trial includes adults aged 18 to 64 years. Both trials are interventional studies, meaning participants receive the vaccine or a comparator and are followed over time.